Share of global RNA therapy pipeline Q1 2024, by phase

Published by
Matej Mikulic,
Jun 7, 2024
As of 1st quarter of 2024, 73 percent of RNAi (ribonucleic acid interference) therapies in the pipeline were still in the preclinical phase. RNA therapies, especially mRNA (messenger RNA) became well-known through the COVID-19 vaccines from Pfizer/BioNTech and from Moderna.

Distribution of RNA therapy pipeline worldwide as of Q1 2024, by phase

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

2024

Region

Worldwide

Survey time period

as of Q1 2024

Supplementary notes

RNA = ribonucleic acid.
RNAi = ribonucleic acid interference.
mRNA = messenger ribonucleic acid.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Coronavirus: the pharma and medtech response "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Coronavirus: the pharma and medtech response

Pharma - before the pandemic

6

Treatments and vaccines

8

Focus: BioNTech and Moderna

7

Opinions on COVID-19 vaccines

6

Business impact

4

Medtech - before the pandemic

5

Ventilators and testing

7

Further related statistics

10

Further Content: You might find this interesting as well

Statistics

Topics

mRNA technologyBiotech drugsBiotechnology industry in Germany Biotechnology in EuropeCoronavirus (COVID-19) vaccines and treatments
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.